Cytogenetic analysis of in vivo and in vitro matured oocytes derived from naturally cycling and stimulated mice.
The objective of the study was to analyze the potential role of follicle stimulating hormone (FSH) in cytogenetic changes of in vivo and in vitro matured mouse oocytes and to determine whether the lower developmental potential of immature oocytes is due to a higher incidence of abnormalities in meiotic spindle organization and chromosome alignment as well as aneuploidy. In vivo matured oocytes were collected from naturally ovulated and superovulated (5.0 I U of recombinant follicle-stimulating hormone [rec-FSH] + recombinant human chorionic gonadotropin [rec-HCG]) mice. Immature oocytes were retrieved from naturally cycling mice and from mice primed with rec-FSH for 48 h. The immature oocytes were cultured 18 h for in vitro maturation (IVM). In vivo and in vitro matured oocytes were assessed for the meiotic spindle organization and chromosome alignment as well as aneuploidy. There was no significant difference of meiotic spindle organization, chromosomal alignment and aneuploidy between in vivo and in vitro matured oocytes derived from naturally cycling and stimulated mice. Therefore, the lower developmental potential of immature oocytes does not appear to be directly related to the incidence of abnormal meiotic spindle organization and chromosome alignment or to aneuploidy.
The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Lan
L
Xu
Yue
Y
Wang
Ping
P
Zhou
Yun-Xia
YX
Cao
Tian-Hua
TH
Huang
Ri-Cheng
RC
Chian
D000782:Aneuploidy; D000818:Animals; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D020090:Chromosome Segregation / Q000187:drug effects; D020732:Cytogenetic Analysis; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D008540:Meiosis / Q000187:drug effects; D051379:Mice; D009865:Oocytes / Q000187:drug effects*; D009866:Oogenesis / Q000187:drug effects* / Q000235:genetics; D010062:Ovulation Induction; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors
D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone